The modern view of an outpatient physician on the diagnosis of adipokines in obese patients

The global obesity epidemic requires innovative diagnostic approaches for patient stratification by metabolic risk. Traditional assessment methods based primarily on body mass index inadequately reflect the heterogeneous nature of obesity. Adipokines — biologically active molecules secreted by adipose tissue — represent promising biomarkers for personalized approach to diagnosis and treatment of obese patients in outpatient settings. Aim. To analyze the current state of adipokine diagnostics in clinical practice and evaluate their potential in stratifying obese patients to optimize therapeutic interventions in ambulatory healthcare. Methods. Current literature on adipokine profiles in obesity was analyzed, focusing on clinically relevant biomarkers including adiponectin, leptin, resistin, visfatin and novel adipokines, with assessment of their diagnostic and prognostic value. Results. It was established that adipokine panels have high prognostic value for metabolic risk stratification. Decreased adiponectin levels combined with elevated leptin resistance markers demonstrate high informativeness for predicting metabolic syndrome development. Novel adipokines show promise for early detection of insulin resistance and cardiovascular risk. Adipokine-based diagnostics opens new opportunities for personalized obesity management, providing targeted intervention strategies and optimal resource allocation in the ambulatory care system.